Abstract #4413
Neuroprotective effects of Chronic Oral Methylene Blue Treatment in Mild Traumatic Brain Injury
Lora Talley Watts 1 , Michael O'Boyle 1 , Robert Cole Boggs 1 , Shiliang Huang 1 , Justin Alexander Long 1 , Qiang Shen 1 , and Timothy Duong 1
1
Research Imaging Institute, University of
Texas Health Science Center at San Antonio, San Antonio,
TX, United States
Methylene blue (MB) has energy-enhancing and antioxidant
properties. We have previously showed that a single
intravenous MB dose reduces lesion volume, behavioral
deficits in animal model of mild traumatic brain injury
(TBI). This study evaluated the efficacy of chronic oral
MB administration on mild TBI by longitudinally
measuring lesion volume and functional outcome. We found
that chronic oral MB treatment minimized lesion volume
and functional deficits compared to vehicle-treated
animals. MB has an excellent safety profile and is
clinically approved for other indications. MB clinical
trials on TBI can thus be readily explored.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Click here for more information on becoming a member.
